Rituximab and bortezomib (RB): a new effective regimen for refractory or relapsed indolent lymphomas View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2015-01

AUTHORS

Hou Yun, Hui lai Zhang, Hua-qing Wang

ABSTRACT

This study was conducted to evaluate the efficacy and safety of rituximab and Bortezomib in relapsed or refractory indolent B cell non-Hodgkin's lymphoma (NHL). Treatments consisted of rituximab 375 mg/m(2), i.v. on days 1, 8, 15, and 22 of cycle 1 and on day one of cycles 2-5, bortezomib 1.6 mg/m(2), given by intravenous injection (3-s to 5-s bolus) on days 1, 8, 15, and 22 of a maximum of five cycles. The primary end points were the overall survival (OS) and progression-free survival (PFS). Secondary endpoints included response rate (ORR; CR) and toxicities. From January 2008 to December 2010, 60 successive patients at Tianjin cancer hospital lymphoma department were enrolled in this study. All patients were recurrent or refractory indolent B cell NHL, including follicular lymphoma grades 1-2 (n = 35), small lymphocytic lymphoma/chronic lymphocytic leukemia (LL/CLL; n = 16) and marginal zone lymphoma (n = 9). The median follow-up time was 30 months (range 12-48). The overall response rate was 70.0 %, with a CR/CRu rate of 31.7 %. The 2-year OS and PFS of all patients were 75.0 and 41.0 %, respectively. Grade 3-4 neutropenia and thrombocytopenia occurred in 10 and 3.3 % of patients, respectively. Higher IPI and refractory disease were independently associated with worse survival and PFS. RB chemotherapy in patients with refractory or relapsed indolent B cell NHL was effective with low toxicity. More... »

PAGES

353

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12032-014-0353-5

DOI

http://dx.doi.org/10.1007/s12032-014-0353-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1017820602

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25511319


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bortezomib", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoma, B-Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proportional Hazards Models", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rituximab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Tianjin Medical University Cancer Institute and Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411918.4", 
          "name": [
            "Lymphoma Department of Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China", 
            "Sino-US Center for Lymphoma and Leukemia, Tianjin, China", 
            "Tianjin Key Laboratory of Cancer Prevention and Therapy, 300060, Tianjin, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yun", 
        "givenName": "Hou", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tianjin Medical University Cancer Institute and Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411918.4", 
          "name": [
            "Lymphoma Department of Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China", 
            "Sino-US Center for Lymphoma and Leukemia, Tianjin, China", 
            "Tianjin Key Laboratory of Cancer Prevention and Therapy, 300060, Tianjin, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Hui lai", 
        "id": "sg:person.01120221150.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01120221150.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tianjin Medical University Cancer Institute and Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411918.4", 
          "name": [
            "Lymphoma Department of Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China", 
            "Sino-US Center for Lymphoma and Leukemia, Tianjin, China", 
            "Tianjin Key Laboratory of Cancer Prevention and Therapy, 300060, Tianjin, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Hua-qing", 
        "id": "sg:person.01372344523.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01372344523.47"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-14-0805", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000278580"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(11)70150-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003244239"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-07-1254", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005473203"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2009-08-233155", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007281374"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bjh.12991", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011599918"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/17425247.2014.945419", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024130566"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archinternmed.2007.125", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031481210"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-014-1646-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038009235", 
          "https://doi.org/10.1007/s12185-014-1646-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/14656566.2014.965142", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040126600"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bjh.13101", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042922510"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.32.1844", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043238900"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2010-11-314708", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045041729"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.molonc.2014.08.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045065971"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.09.2403", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045509899"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2012.11.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047036200"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074454436", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078981825", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1995.13.1.140", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082512482"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-01", 
    "datePublishedReg": "2015-01-01", 
    "description": "This study was conducted to evaluate the efficacy and safety of rituximab and Bortezomib in relapsed or refractory indolent B cell non-Hodgkin's lymphoma (NHL). Treatments consisted of rituximab 375\u00a0mg/m(2), i.v. on days 1, 8, 15, and 22 of cycle 1 and on day one of cycles 2-5, bortezomib 1.6\u00a0mg/m(2), given by intravenous injection (3-s to 5-s bolus) on days 1, 8, 15, and 22 of a maximum of five cycles. The primary end points were the overall survival (OS) and progression-free survival (PFS). Secondary endpoints included response rate (ORR; CR) and toxicities. From January 2008 to December 2010, 60 successive patients at Tianjin cancer hospital lymphoma department were enrolled in this study. All patients were recurrent or refractory indolent B cell NHL, including follicular lymphoma grades 1-2 (n\u00a0=\u00a035), small lymphocytic lymphoma/chronic lymphocytic leukemia (LL/CLL; n\u00a0=\u00a016) and marginal zone lymphoma (n\u00a0=\u00a09). The median follow-up time was 30\u00a0months (range 12-48). The overall response rate was 70.0\u00a0%, with a CR/CRu rate of 31.7\u00a0%. The 2-year OS and PFS of all patients were 75.0 and 41.0\u00a0%, respectively. Grade 3-4 neutropenia and thrombocytopenia occurred in 10 and 3.3\u00a0% of patients, respectively. Higher IPI and refractory disease were independently associated with worse survival and PFS. RB chemotherapy in patients with refractory or relapsed indolent B cell NHL was effective with low toxicity. ", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s12032-014-0353-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094524", 
        "issn": [
          "1357-0560", 
          "1559-131X"
        ], 
        "name": "Medical Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "32"
      }
    ], 
    "name": "Rituximab and bortezomib (RB): a new effective regimen for refractory or relapsed indolent lymphomas", 
    "pagination": "353", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "54e8cb584f6beaff5f35b502409217b3c661c684f5f0657981f353bd615788e9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25511319"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9435512"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12032-014-0353-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1017820602"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12032-014-0353-5", 
      "https://app.dimensions.ai/details/publication/pub.1017820602"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T19:11", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8678_00000521.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs12032-014-0353-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12032-014-0353-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12032-014-0353-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12032-014-0353-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12032-014-0353-5'


 

This table displays all metadata directly associated to this object as RDF triples.

205 TRIPLES      21 PREDICATES      64 URIs      38 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12032-014-0353-5 schema:about N0192ae6ca86c426082ba50e6836bd431
2 N1b09d641f92f4e00bbed4f1fa3130075
3 N2d7002ca0dbd4ab78955bd356b10403f
4 N32afea56ffb546dc837f09e67155beed
5 N403b89858f4940c9a9ae7749584f0844
6 N56bbe23fd60344ef9a0b4aaa904a8d1e
7 N619294e51b97490b958817254dc6ab20
8 N76b92335d77c4e02a2189bad594c7a5e
9 N80374410b9a94f3f9746539dd9e1a6d9
10 N8c1137bc852f46f285fc7807b5d2304a
11 N8d6c0b77a5ca477babb7a89cd6c4a1b3
12 N9a95681df42d41b1a13378cd23b644ab
13 Nbdd27e8a5879423fad29ff487d9f0cdc
14 Nc9e0d9509ce5445da1c623b4f6e5fd1d
15 Nde7f3672500c4ac9b8083f2611f0d2bb
16 Nfcd93a9a456240729684598ca808be60
17 Nfe3ffb0575024df0ac7d432e94f974e1
18 anzsrc-for:11
19 anzsrc-for:1112
20 schema:author Ne05d38bb0663492f97ab3be34d2f77c8
21 schema:citation sg:pub.10.1007/s12185-014-1646-3
22 https://app.dimensions.ai/details/publication/pub.1074454436
23 https://app.dimensions.ai/details/publication/pub.1078981825
24 https://doi.org/10.1001/archinternmed.2007.125
25 https://doi.org/10.1016/j.ejca.2012.11.015
26 https://doi.org/10.1016/j.molonc.2014.08.010
27 https://doi.org/10.1016/s1470-2045(11)70150-4
28 https://doi.org/10.1111/bjh.12991
29 https://doi.org/10.1111/bjh.13101
30 https://doi.org/10.1158/1078-0432.ccr-07-1254
31 https://doi.org/10.1158/1078-0432.ccr-14-0805
32 https://doi.org/10.1182/blood-2009-08-233155
33 https://doi.org/10.1182/blood-2010-11-314708
34 https://doi.org/10.1200/jco.1995.13.1.140
35 https://doi.org/10.1200/jco.2006.09.2403
36 https://doi.org/10.1200/jco.2010.32.1844
37 https://doi.org/10.1517/14656566.2014.965142
38 https://doi.org/10.1517/17425247.2014.945419
39 schema:datePublished 2015-01
40 schema:datePublishedReg 2015-01-01
41 schema:description This study was conducted to evaluate the efficacy and safety of rituximab and Bortezomib in relapsed or refractory indolent B cell non-Hodgkin's lymphoma (NHL). Treatments consisted of rituximab 375 mg/m(2), i.v. on days 1, 8, 15, and 22 of cycle 1 and on day one of cycles 2-5, bortezomib 1.6 mg/m(2), given by intravenous injection (3-s to 5-s bolus) on days 1, 8, 15, and 22 of a maximum of five cycles. The primary end points were the overall survival (OS) and progression-free survival (PFS). Secondary endpoints included response rate (ORR; CR) and toxicities. From January 2008 to December 2010, 60 successive patients at Tianjin cancer hospital lymphoma department were enrolled in this study. All patients were recurrent or refractory indolent B cell NHL, including follicular lymphoma grades 1-2 (n = 35), small lymphocytic lymphoma/chronic lymphocytic leukemia (LL/CLL; n = 16) and marginal zone lymphoma (n = 9). The median follow-up time was 30 months (range 12-48). The overall response rate was 70.0 %, with a CR/CRu rate of 31.7 %. The 2-year OS and PFS of all patients were 75.0 and 41.0 %, respectively. Grade 3-4 neutropenia and thrombocytopenia occurred in 10 and 3.3 % of patients, respectively. Higher IPI and refractory disease were independently associated with worse survival and PFS. RB chemotherapy in patients with refractory or relapsed indolent B cell NHL was effective with low toxicity.
42 schema:genre research_article
43 schema:inLanguage en
44 schema:isAccessibleForFree false
45 schema:isPartOf N0757c926c07f4ac99d455ca4770496d4
46 Nc7aa23a876694a91bf3e086d061eb59b
47 sg:journal.1094524
48 schema:name Rituximab and bortezomib (RB): a new effective regimen for refractory or relapsed indolent lymphomas
49 schema:pagination 353
50 schema:productId N3bad5142e4ef4d2b962bcd269f7c94ba
51 N7ab80f0061884509afe463e712d73b01
52 N8c4cb07f748b4b14a124f09a3f56b995
53 N8cc6ce98b6da48aaa8b0767358619406
54 Ne21a3ce59e8241439701593dcb90e3ce
55 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017820602
56 https://doi.org/10.1007/s12032-014-0353-5
57 schema:sdDatePublished 2019-04-10T19:11
58 schema:sdLicense https://scigraph.springernature.com/explorer/license/
59 schema:sdPublisher N64f2c5d889a14f2a8a3c08356eb75fa9
60 schema:url http://link.springer.com/10.1007%2Fs12032-014-0353-5
61 sgo:license sg:explorer/license/
62 sgo:sdDataset articles
63 rdf:type schema:ScholarlyArticle
64 N0192ae6ca86c426082ba50e6836bd431 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Proportional Hazards Models
66 rdf:type schema:DefinedTerm
67 N0757c926c07f4ac99d455ca4770496d4 schema:volumeNumber 32
68 rdf:type schema:PublicationVolume
69 N1b09d641f92f4e00bbed4f1fa3130075 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Young Adult
71 rdf:type schema:DefinedTerm
72 N2d7002ca0dbd4ab78955bd356b10403f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Adult
74 rdf:type schema:DefinedTerm
75 N32afea56ffb546dc837f09e67155beed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Lymphoma, B-Cell
77 rdf:type schema:DefinedTerm
78 N3bad5142e4ef4d2b962bcd269f7c94ba schema:name pubmed_id
79 schema:value 25511319
80 rdf:type schema:PropertyValue
81 N403b89858f4940c9a9ae7749584f0844 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Antineoplastic Combined Chemotherapy Protocols
83 rdf:type schema:DefinedTerm
84 N56bbe23fd60344ef9a0b4aaa904a8d1e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Neoplasm Recurrence, Local
86 rdf:type schema:DefinedTerm
87 N619294e51b97490b958817254dc6ab20 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Bortezomib
89 rdf:type schema:DefinedTerm
90 N630066497a524805ab6c74355012ffaf schema:affiliation https://www.grid.ac/institutes/grid.411918.4
91 schema:familyName Yun
92 schema:givenName Hou
93 rdf:type schema:Person
94 N64f2c5d889a14f2a8a3c08356eb75fa9 schema:name Springer Nature - SN SciGraph project
95 rdf:type schema:Organization
96 N76b92335d77c4e02a2189bad594c7a5e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Rituximab
98 rdf:type schema:DefinedTerm
99 N7ab80f0061884509afe463e712d73b01 schema:name readcube_id
100 schema:value 54e8cb584f6beaff5f35b502409217b3c661c684f5f0657981f353bd615788e9
101 rdf:type schema:PropertyValue
102 N80374410b9a94f3f9746539dd9e1a6d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Male
104 rdf:type schema:DefinedTerm
105 N8c1137bc852f46f285fc7807b5d2304a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Middle Aged
107 rdf:type schema:DefinedTerm
108 N8c4cb07f748b4b14a124f09a3f56b995 schema:name doi
109 schema:value 10.1007/s12032-014-0353-5
110 rdf:type schema:PropertyValue
111 N8cc6ce98b6da48aaa8b0767358619406 schema:name nlm_unique_id
112 schema:value 9435512
113 rdf:type schema:PropertyValue
114 N8d6c0b77a5ca477babb7a89cd6c4a1b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Adolescent
116 rdf:type schema:DefinedTerm
117 N9a95681df42d41b1a13378cd23b644ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Aged
119 rdf:type schema:DefinedTerm
120 Nbdd27e8a5879423fad29ff487d9f0cdc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Retrospective Studies
122 rdf:type schema:DefinedTerm
123 Nc7aa23a876694a91bf3e086d061eb59b schema:issueNumber 1
124 rdf:type schema:PublicationIssue
125 Nc9e0d9509ce5445da1c623b4f6e5fd1d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Humans
127 rdf:type schema:DefinedTerm
128 Nde7f3672500c4ac9b8083f2611f0d2bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Disease-Free Survival
130 rdf:type schema:DefinedTerm
131 Ne05d38bb0663492f97ab3be34d2f77c8 rdf:first N630066497a524805ab6c74355012ffaf
132 rdf:rest Nfd8c12c0de43420ba4fe12f872dd4503
133 Ne21a3ce59e8241439701593dcb90e3ce schema:name dimensions_id
134 schema:value pub.1017820602
135 rdf:type schema:PropertyValue
136 Nf28e558e263b46d0bb14850bed68cee3 rdf:first sg:person.01372344523.47
137 rdf:rest rdf:nil
138 Nfcd93a9a456240729684598ca808be60 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Female
140 rdf:type schema:DefinedTerm
141 Nfd8c12c0de43420ba4fe12f872dd4503 rdf:first sg:person.01120221150.28
142 rdf:rest Nf28e558e263b46d0bb14850bed68cee3
143 Nfe3ffb0575024df0ac7d432e94f974e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Kaplan-Meier Estimate
145 rdf:type schema:DefinedTerm
146 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
147 schema:name Medical and Health Sciences
148 rdf:type schema:DefinedTerm
149 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
150 schema:name Oncology and Carcinogenesis
151 rdf:type schema:DefinedTerm
152 sg:journal.1094524 schema:issn 1357-0560
153 1559-131X
154 schema:name Medical Oncology
155 rdf:type schema:Periodical
156 sg:person.01120221150.28 schema:affiliation https://www.grid.ac/institutes/grid.411918.4
157 schema:familyName Zhang
158 schema:givenName Hui lai
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01120221150.28
160 rdf:type schema:Person
161 sg:person.01372344523.47 schema:affiliation https://www.grid.ac/institutes/grid.411918.4
162 schema:familyName Wang
163 schema:givenName Hua-qing
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01372344523.47
165 rdf:type schema:Person
166 sg:pub.10.1007/s12185-014-1646-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038009235
167 https://doi.org/10.1007/s12185-014-1646-3
168 rdf:type schema:CreativeWork
169 https://app.dimensions.ai/details/publication/pub.1074454436 schema:CreativeWork
170 https://app.dimensions.ai/details/publication/pub.1078981825 schema:CreativeWork
171 https://doi.org/10.1001/archinternmed.2007.125 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031481210
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1016/j.ejca.2012.11.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047036200
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1016/j.molonc.2014.08.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045065971
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1016/s1470-2045(11)70150-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003244239
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1111/bjh.12991 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011599918
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1111/bjh.13101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042922510
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1158/1078-0432.ccr-07-1254 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005473203
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1158/1078-0432.ccr-14-0805 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000278580
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1182/blood-2009-08-233155 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007281374
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1182/blood-2010-11-314708 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045041729
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1200/jco.1995.13.1.140 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082512482
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1200/jco.2006.09.2403 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045509899
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1200/jco.2010.32.1844 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043238900
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1517/14656566.2014.965142 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040126600
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1517/17425247.2014.945419 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024130566
200 rdf:type schema:CreativeWork
201 https://www.grid.ac/institutes/grid.411918.4 schema:alternateName Tianjin Medical University Cancer Institute and Hospital
202 schema:name Lymphoma Department of Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
203 Sino-US Center for Lymphoma and Leukemia, Tianjin, China
204 Tianjin Key Laboratory of Cancer Prevention and Therapy, 300060, Tianjin, China
205 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...